CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Beginning balance		$ (34,764)	$ (67,485)	$ (70,322)	$ (52,881)
Share-based compensation		909	196	1,607	599
Issuance of common stock and warrants, net of issuance cost				41,343
Note receivable payment		4,000
Share-based compensation related to restricted stock award		505		505
Exercise of warrants		472		472
Net loss for the period		(4,437)	(3,560)	(6,920)	(18,567)
Ending balance		(33,315)	(70,849)	(33,315)	(70,849)
Common Stock [Member]
Beginning balance		$ 33	$ 15	$ 15	$ 15
Beginning balance (in shares)	[1]	32,442,636	14,838,213	14,838,213	14,838,213
Issuance of common stock and warrants, net of issuance cost				$ 18
Issuance of common stock and warrants, net of issuance cost (in shares)	[1]			17,604,423
Share-based compensation related to restricted stock award (in shares)	[1]	694,073		694,073
Exercise of warrants (in shares)	[1]	200,000		200,000
Ending balance		$ 33	$ 15	$ 33	$ 15
Ending balance (in shares)	[1]	33,336,709	14,838,213	33,336,709	14,838,213
Additional Paid-in Capital [Member]
Beginning balance		$ 308,515	$ 270,060	$ 270,492	$ 269,657
Share-based compensation		909	196	1,607	599
Issuance of common stock and warrants, net of issuance cost				41,325
Note receivable payment		4,000
Share-based compensation related to restricted stock award		505		505
Exercise of warrants		472		472
Ending balance		314,401	270,256	314,401	270,256
Accumulated Deficit [Member]
Beginning balance		(343,312)	(337,560)	(340,829)	(322,553)
Net loss for the period		(4,437)	(3,560)	(6,920)	(18,567)
Ending balance		$ (347,749)	$ (341,120)	$ (347,749)	$ (341,120)

[1] Common Stock, $0.001 par value; Authorized – as of September 30, 2020 and 2019 - 120,000,000 and 350,000,000, respectively.